Seragon names Tony Coles to board
This article was originally published in Scrip
San Diego-based Seragon Pharmaceuticals, a clinical-stage biotechnology company focused on the development of drugs for hormone-driven cancers, has named N Anthony (Tony) Coles to its board of directors. Most recently, Dr Coles was president, chief executive officer and chair of the board of Onyx Pharmaceuticals, a global biopharmaceutical company acquired by Amgen in October 2013. He is currently a member of the board of directors of McKesson Corporation, vice-chair of the board of trustees for Johns Hopkins University, and a member of the board of trustees for Johns Hopkins Medicine. Dr Coles is also a member of the board of the US Olympic and Paralympic Foundation.
You may also be interested in...
A rush in the 2010s of high-tech and digital companies focused on women’s health and wellbeing are maturing, adding weight to the more traditional women's health market that has struggled to get attention from investors in the past.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
A selection of articles you might have missed from September 2020, including exclusive interviews with industry leaders and a review of value-based contract approaches in the US.